Newly marketed tissue markers for malignant mesothelioma: Immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies
- 1 August 1997
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 28 (8) , 929-937
- https://doi.org/10.1016/s0046-8177(97)90008-3
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The Roles of Immunohistochemistry and Electron Microscopy in Distinguishing Epithelial Mesothelioma of the Pleura from AdenocarcinomaAdvances in Anatomic Pathology, 1996
- Malignant mesothelioma of the pleura: interobserver variability.Journal of Clinical Pathology, 1995
- ME1-Antibody labelling of primary bronchogenic tumours and extrapulmonary malignanciesLung Cancer, 1994
- Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibodyDiagnostic Cytopathology, 1992
- Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung AdenocarcinomaThe American Journal of Surgical Pathology, 1992
- Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesotheliomaThe Journal of Pathology, 1991
- Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinomaInternational Journal of Cancer, 1988
- Monoclonal antibodies to human malignant mesotheliomaJournal of Clinical Immunology, 1987
- New marker for mesothelioma: an immunoperoxidase study.Journal of Clinical Pathology, 1986
- Diagnosis of pleural malignant mesothelioma in life—a practical approachThe Journal of Pathology, 1984